
Key Points
- 01Medtronic plans to acquire Contego Medical for $380 million plus potential additional payments
- 02Deal is expected to close in Medtronic’s fiscal third quarter, pending conditions
- 03Acquisition adds FDA-approved Neuroguard IEP Direct and Excipio devices to Medtronic’s portfolio
- 04Medtronic expects minimal EPS dilution in FY27–FY28, then neutral to accretive
Medtronic announces $380 million Contego Medical deal
Medtronic has agreed to acquire privately held Contego Medical in a transaction valued at $380 million, with potential additional payments following the acquisition. The company expects to complete the deal in the third quarter of its fiscal year, subject to customary closing conditions. Medtronic anticipates the acquisition will be minimally dilutive to adjusted earnings per share in fiscal years 2027 and 2028, and neutral to accretive thereafter.
The planned acquisition is intended to strengthen Medtronic’s position in the treatment of carotid artery disease and peripheral vascular conditions. It expands the company’s portfolio of carotid technologies and peripheral vascular treatments while deepening its presence in stroke prevention and clot-removal devices.
Expansion of carotid therapy portfolio
The deal includes Contego’s FDA-approved Neuroguard IEP Direct System, described as the first transcarotid artery revascularization system with integrated embolic protection and flow reversal. This system is designed for carotid artery treatment, addressing disease in the major blood vessels that supply blood to the brain.
Neuroguard IEP Direct was evaluated in the prospective, multicenter PERFORMANCE III study. At 30 days, the study reported zero strokes, zero neurological deaths, zero cranial nerve injuries, and zero myocardial infarctions among treated patients. These outcomes are highlighted as part of the clinical performance profile of the device.
Contego’s broader portfolio also includes the Neuroguard IEP System and the Excipio thrombectomy device family. These products are focused on embolic protection and clot removal, further broadening the treatment options Medtronic can offer for vascular disease management.
Peripheral vascular treatments and strategic fit
In addition to carotid therapies, the acquisition brings Excipio thrombectomy devices, which are used for removing blood clots from peripheral vessels. These devices will complement Medtronic’s existing Liberant thrombectomy system for peripheral vascular disease treatment, creating a more complete toolkit for clinicians managing clot-related conditions outside the brain.
The transaction builds on an exclusive U.S. distribution agreement between Medtronic and Contego that was announced in January 2025. Moving from a distribution partnership to full ownership allows Medtronic to fully integrate Contego’s technologies into its vascular health portfolio and commercial organization.
Contego Medical was founded by physicians Ravish Sachar, MD, and Jay Yadav, MD, and has been backed by healthcare-focused investors. Medtronic, headquartered in Galway, Ireland, employs more than 90,000 people across over 150 countries, providing the scale to further develop and distribute Contego’s carotid and peripheral vascular products globally.
Key Takeaways
- 01Medtronic is using targeted M&A to deepen its capabilities in carotid and peripheral vascular therapies with a $380 million Contego acquisition.
- 02The Neuroguard IEP Direct System and Excipio devices give Medtronic additional clinically tested tools in stroke prevention and clot removal.
- 03Expected minimal earnings dilution in FY27–FY28 and neutral to accretive impact thereafter suggests a measured financial effect from the deal.
References
- https://finance.yahoo.com/healthcare/articles/medtronic-acquire-contego-medical-expanding-114500980.html?.tsrc=rss
- https://www.stocktitan.net/news/MDT/medtronic-to-acquire-contego-medical-expanding-access-to-next-djs7ahothseb.html
- https://de.investing.com/news/company-news/medtronic-ubernimmt-contego-medical-fur-380-millionen-93CH-3769864
- https://uk.investing.com/news/stock-market-news/medtronic-to-acquire-contego-medical-for-380-million-93CH-4984354